Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022

Rhea-AI Summary

Finch Therapeutics Group (Nasdaq: FNCH) announced a conference call and live webcast on May 16, 2022, at 8:00 am ET to discuss updates on its development programs. The call can be accessed at (833) 649-1186 for domestic callers and (270) 823-1080 for international callers, using conference ID 8451806. Finch specializes in microbiome therapeutics, with lead candidate CP101 in late-stage development for C. difficile infection prevention. Finch has also received Breakthrough Therapy and Fast Track designations from the FDA.

SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery^® platform to develop a novel class of orally administered biological drugs, today announced it will host a conference call and live webcast on Monday, May 16, 2022 at 8:00am ET to discuss updates to its development programs and other business highlights.

The conference call can be accessed by dialing (833) 649-1186 (domestic) or (270) 823-1080 (international) and entering conference ID 8451806. The live webcast can be accessed by visiting the ‘Investors & News’ section of the Finch Therapeutics website and selecting ‘Events & Presentations’. The webcast will be archived on the Finch website for approximately 30 days following the event.

About Finch Therapeutics

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease. Finch routinely posts information that may be important to its investors on its website at www.finchtherapeutics.com. Finch encourages investors to consult the “Investors & News” section of its website regularly.

Human-First Discovery^® is a registered trademark of Finch Therapeutics Group, Inc.

Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com

FAQ

What is the date of Finch Therapeutics' upcoming conference call?

Finch Therapeutics' conference call is scheduled for May 16, 2022.

How can I access the Finch Therapeutics conference call?

The conference call can be accessed by calling (833) 649-1186 domestically or (270) 823-1080 internationally.

What is Finch Therapeutics known for?

Finch Therapeutics is known for developing microbiome therapeutics, including its lead candidate CP101 for preventing C. difficile infections.

What designations has Finch Therapeutics received from the FDA?

Finch Therapeutics has received Breakthrough Therapy and Fast Track designations from the FDA for its lead candidate, CP101.

Where can I find more information about Finch Therapeutics?

More information about Finch Therapeutics can be found on their official website under the 'Investors & News' section.